News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Forest Laboratories, Inc., Gedeon Richter Ltd. May Do Additional Phase II Cariprazine Trial; Drug Misses Overall Goal
August 30, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Gedeon Richter Nyrt., Hungary’s largest drugmaker, said that the Phase II clinical trial of Cariprazine for bipolar depression produced no “statistically significant” result compared with placebo treatment.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
·
3 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
March 10, 2026
·
2 min read
·
Tristan Manalac
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
March 9, 2026
·
2 min read
·
Heather McKenzie